Pharmacokinetics and metabolism of all-trans-and 13-cis-retinoic acid in pulmonary emphysema patients

Journal of Clinical Pharmacology

Volumn 48, Issue 1, 2008, Pages 96-107

  Muindi, Josephia R ^b,i   Roth, Michael D ^c   Wise, Robert A ^g   Connett, John E ^h   O'Connor, George T ^d   Ramsdell, Joe W ^e   Schluger, Neil W ^f   Romkes, Marjorie ^b   Branch, Robert A ^b   Sciurba, Frank C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BOSTON UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

ⁱ ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

13 cRA; ATRA; Emphysema; Metabolism; Plasma pharmacokinetics; Retinoid

Indexed keywords

ISOTRETINOIN; PLACEBO; RETINOIC ACID;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG METABOLISM; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; LUNG DIFFUSION CAPACITY; LUNG EMPHYSEMA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TREATMENT OUTCOME;

AGED; AREA UNDER CURVE; CAPSULES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HALF-LIFE; HUMANS; ISOTRETINOIN; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; PULMONARY EMPHYSEMA; STEREOISOMERISM; TIME FACTORS; TRETINOIN;

EID: 37349051491     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007309701     Document Type: Article

References (35)

1. Massaro GD, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med. 1997 ; 3: 675-677.
2. Belloni PN, Garvin L., Mao CP, Bailey-Healy I., Leaffer D. Effects of all-trans-retinoic acid in promoting alveolar repair. Chest. 2000 ; 17: 235S - 241S.
3. Ishizawa K., Kubo H., Yamada M., et al. Bone marrow-derived cells contribute to lung regeneration after elastase-induced pulmonary emphysema. FEBS Lett. 2004 ; 556: 249-252.
4. Ofulue AF, Xiang AF, Yang Y., Belloni PN Retinoids reverse cigarette smoke-induced emphysema in rats. Am J Respir Crit Care Med. 2002 ; 165: A137.
5. Massaro GD, Massaro D., Chambon P. Retinoic acid receptor-alpha regulates pulmonary alveolus formation in mice after, but not during, perinatal period. Am J Physiol Lung Cell Mol Physiol. 2003 ; 284: L431 - L433.
6. Massaro GD, Massaro D. Postnatal treatment with retinoic acid increases the number of pulmonary alveoli in rats. Am J Physiol. 1996 ; 270: L305 - L310.
7. Massaro D., Teich N., Maxwell S., Massaro GD, Whitney P. Postnatal development of alveoli: regulation and evidence for a critical period in rats. J Clin Invest. 1985 ; 76: 1297-1305.
8. Shenai JP, Kennedy KA, Chytil F., Stahlman MT Clinical trial of vitamin A supplementation in infants susceptible to bronchopulmonary dysplasia. J Pediatr. 1987 ; 11: 269-277.
9. McSorley LC, Daly AK Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation. Biochem Pharmacol. 2000 ; 60: 517-526.
10. Chen H., Howald WN, Juchau MR Biosynthesis of all-trans-retinoic acid from all-trans-retinol: catalysis of all-trans-retinol oxidation by human P-450 cytochromes. Drug Metab Dispos. 2000 ; 28: 315-322.
11. Liu C., Russell RM, Wang X-D. Exposing ferrets to cigarette smoke and a pharmacological dose of β-carotene supplementation enhance in vitro retinoic acid catabolism in lungs via induction of cytochrome P450 enzymes. J Nutr. 2003 ; 133: 173-179.
12. Ray WJ, Bain G., Yao M., Gottlieb DI CYP26, a novel mammalian cytochrome P450, is induced by retinoic acid and defines a new family. J Biol Chem. 1997 ; 272: 18702-18708.
13. MacLean G., Abu-Abed S., Dolle P., Tahayato A., Chambon P., Petkovich M. Cloning of a novel retinoic-acid metabolizing cytochrome P450, Cyp26B1, and comparative expression analysis with Cyp26A1 during early murine development. Mech Dev. 2001 ; 107: 195-201.
14. Taimi M., Helvig C., Wisniewski J., et al. A novel human cytochrome P450. J Biol Chem. 2004 ; 279: 77-85.
15. Abu-Abed S., Dolle P., Metzger D., Beckett B., Chambon P., Petkovich M. The retinoic acid-metabolizing enzyme, CYP26A1, is essential for normal hindbrain patterning, vertebral identity, and development of posterior structures. Genes Dev. 2001 ; 15: 226-240.
16. Niederreither K., Abu-Abed S., Schuhbaur B., Petkovich M., Chambon P., Dolle P. Genetic evidence that oxidative derivatives of retinoic acid are not involved in retinoid signaling during mouse development. Nat Genet. 2002 ; 31: 84-88.
17. Levin AA Receptors as tools for understanding the toxicity of retinoids. Toxicol Lett. 1995 ; 82-83: 91-97.
18. Kim Y-M., Sharma RP, Li JK Characterization of heterologously expressed recombinant retinoic acid receptors with natural or synthetic retinoids. J Biochem Toxicol. 1994 ; 9: 225-234.
19. Muindi JR, Frankel SR, Huselton C., et al. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res. 1992 ; 52: 2138-2142.
20. Smith MA, Adamson PC, Balis FM, et al. Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. J Clin Oncol. 1992 ; 10: 1666-1673.
21. Trump DL, Smith DC, Stiff D., et al. A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis. Cancer Chemother Pharmacol. 1997 ; 39: 349-356.
22. Conley BA, Egorin MJ, Sridhara R., et al. Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics. Cancer Chemother Pharmacol. 1997 ; 39: 291-299.
23. Muindi J., Frankel SR, Miller WH Jr, et al. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance " in patients with acute promyelocytic leukemia. Blood. 1992 ; 79: 299-303.
24. Kerr IG, Lippman ME, Jenkins J., Myers CE Pharmacology of 13-cis-retinoic acid in humans. Cancer Res. 1982 ; 42: 2069-2073.
25. Goodman GE, Einspahr JG, Alberts DS, et al. Pharmacokinetics of 13-cis-retinoic acid in patients with advanced cancer. Cancer Res. 1982 ; 42: 2087-2091.
26. Brazzell RK, Vane FM, Ehmann CW, Colburn WA Pharmacokinetics of isotretinoin during repetitive dosing to patients. Eur J Clin Pharmacol. 1983 ; 24: 695-702.
27. Roth MD, Connett JE, D'Armiento JM, et al, for the FORTE Study Investigators. Feasibility of retinoids for the treatment of emphysema (FORTE) study. Chest. 2006 ; 130: 1334-1345.
28. Bugge Cjl, Rodriguez LC, Vane FM Determination of isotretinoin or etretinate and their major metabolites in human blood by reverse-phase high performance liquid chromatography. J Pharm Biomed Anal. 1985 ; 3: 269-277.
29. El-Metwally TH, Hussein MR, Pour PM, Kuszynski CA, Adrian TE High concentrations of retinoids induce differentiation and late apoptosis in pancreatic cancer cells in vitro. Cancer Biol Ther. 2005 ; 4: 602-611.
30. Idres N., Benoit G., Flexor MA, Lanotte M., Chabot GG Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites. Cancer Res. 2001 ; 61: 700-705.
31. Lanvers C., Reinhardt D., Dubbers A., et al. Pharmacology of all-trans-retinoic acid in children with acute promyelocytic leukemia. Med Pediatr Oncol. 2003 ; 40: 293-301.
32. Adamson PC, Reaman G., Finklestein JZ, et al. Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer. J Clin Oncol. 1997 ; 15: 3330-3337.
33. Rigas JR, Francis PA, Muindi JR, et al. Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. J Natl Cancer Inst. 1993 ; 85: 1921 -1926.
34. Miller VA, Rigas JR, Muindi JR, et al. Modulation of all-trans-retinoic acid pharmacokinetics by liarozole. Cancer Chemother Pharmacol. 1994 ; 34: 522-526.
35. Chiu YY, Roth MD, Kolis S., Rogovitz D., Davies B. Pharmacokinetics of a novel agent, R667, in patients with emphysema. Br J Clin Pharmacol. 2007 ; 63: 527-533.